Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.22 SEK | +2.06% | -27.96% | -57.96% |
Apr. 15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
Apr. 04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
Business Summary
Number of employees: 57
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Drugs
100.0
%
| 8 | 100.0 % | 35 | 100.0 % | +321.54% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
69.1
%
| 8 | 93.3 % | 24 | 69.1 % | +212.12% |
Europe
30.9
%
| - | - | 11 | 30.9 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | Nov. 12 | |
Eva Nordström
COO | Chief Operating Officer | 54 | 11-12-31 |
Chief Tech/Sci/R&D Officer | 52 | 11-10-20 | |
David Augustsson
IRC | Investor Relations Contact | - | - |
Sara Svardgren
HRO | Human Resources Officer | 45 | 18-04-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 | |
Director/Board Member | 73 | 11-03-31 | |
Jennifer Jackson
BRD | Director/Board Member | 71 | 18-12-04 |
Brian Stuglik
BRD | Director/Board Member | 64 | 18-05-16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 211,025,796 | 201,246,562 ( 95.37 %) | 0 | 95.37 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.39% | 28.79M | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+3.00% | 22.19B | |
-16.16% | 21.33B | |
-7.26% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- ONCO Stock
- Company Oncopeptides AB